COlchicine to Prevent PeriprocEdural Myocardial Injury in Percutaneous Coronary Intervention (COPE-PCI): Coronary Microvascular Physiology Pilot Substudy

Table 4

Primary study endpoint, by study drug randomization.

Primary endpoint	Colchicine (n = 24)	Placebo (n = 26)	value
Combined CMVD: (CFR <2.0 or RRR <2.0 or IMR >32)	10 (42)	16 (62)	0.16^§
RRR <2.0 or IMR >32	8 (33)	14 (54)	0.14^§
CFR or RRR <2.0	5 (21)	12 (46)	0.06^§
RRR <2.0	3 (13)	9 (35)	0.10^||
CFR <2.0	5 (21)	12 (46)	0.06^§
IMR >32	6 (25)	8 (31)	0.65^§

Values are n (%), denotes comparison between colchicine vs placebo group, § denotes Chi-squared test, and || denotes Fisher’s exact test.